DEF: Aprea Therapeutics Annual Meeting: Reverse Stock Split Proposed

Aprea Therapeutics, Inc. is holding its 2026 Annual Meeting of Stockholders on June 16, 2026, to vote on key proposals including a potential reverse stock split to maintain Nasdaq listing.

Summary

• Aprea Therapeutics, Inc. is convening its 2026 Annual Meeting of Stockholders virtually on June 16, 2026.
• Key proposals include the election of three Class I directors, ratification of EisnerAmper LLP as the independent auditor, and approval of an amendment to authorize a reverse stock split.
• The reverse stock split, with a ratio between 1-for-3 and 1-for-8, is primarily intended to increase the per-share market price of the Common Stock to comply with Nasdaq's minimum bid price requirement of $1.00.
• Stockholders will also vote on advisory proposals regarding executive compensation and the frequency of future advisory votes on executive compensation.
• The meeting will be held virtually via live webcast, and stockholders of record as of April 21, 2026, are eligible to vote.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as having a neutral to slightly negative sentiment due to the necessity of a reverse stock split to avoid delisting, which indicates underlying stock price performance issues, despite the company's proactive governance and experienced board.

Positives

• The company is proactively addressing potential Nasdaq delisting by proposing a reverse stock split to meet the minimum bid price requirement.
• A strong independent board with diverse expertise in life sciences, finance, and business operations is in place.
• The company has robust corporate governance guidelines and committee structures in place, with a majority of independent directors.
• The Audit Committee has a designated financial expert, ensuring strong oversight of financial reporting.

Negatives

• The company received a deficiency letter from Nasdaq on January 23, 2026, indicating its common stock closing bid price was below the $1.00 minimum for 30 consecutive business days.
• A reverse stock split may be perceived negatively by investors and could potentially decrease liquidity.
• The company has not made any employer match contributions to its 401(k) plan in 2025.

Risks

• Risk of delisting from Nasdaq if the minimum bid price requirement is not met, which could reduce liquidity, visibility, and the ability to raise capital.
• Potential negative investor perception and decreased liquidity following a reverse stock split.
• The reverse stock split may not be sufficient to maintain compliance with all Nasdaq listing requirements.
• Future issuances of authorized but unissued shares could lead to significant dilution for existing stockholders.

Future Outlook

The company is seeking stockholder approval for a reverse stock split to potentially increase its per-share market price and maintain its Nasdaq listing. The Board has the discretion to implement the reverse stock split at any time prior to the 2027 Annual Meeting of Stockholders, or to abandon it.

Management Comments

• "YOUR VOTE IS IMPORTANT. Whether or not you plan to attend the Annual Meeting, we encourage you to review the proxy materials and submit your vote via the Internet, telephone or mail as soon as possible."
• "We believe that effecting the Reverse Split will help us avoid delisting from Nasdaq and any resulting consequences."
• "Our Board of Directors recommends that you vote: FOR the election of each of the director nominees... FOR the ratification of the appointment of EisnerAmper LLP... FOR the approval of an amendment... to effect a reverse stock split... FOR the non-binding advisory vote on the compensation of our named executive officers... FOR the non-binding advisory vote on the frequency of future votes... FOR the approval of the adjournment of the Annual Meeting..."
• "Our Board believes that our current leadership structure is appropriate at this time, with the Company benefiting from our CEOs leadership on the Board, balanced by our independent Chairman."

Industry Context

StockSavvy.ai notes that Aprea Therapeutics' proposal for a reverse stock split is a common strategy employed by biotechnology and other companies facing minimum bid price deficiencies on major exchanges like Nasdaq. This action is often taken to avoid delisting and maintain investor confidence, though its long-term effectiveness in boosting share price and attracting investment can vary.

Corporate Governance

Related Party Transactions

• No related party transactions exceeding $120,000 or 1% of average total assets were disclosed since January 1, 2025, other than standard employment and director compensation arrangements.

Stakeholder Impact

• Shareholders: The proposed reverse stock split aims to improve the stock price to maintain Nasdaq listing, potentially preventing delisting and its negative consequences. However, reverse splits can be viewed negatively and may not guarantee a sustained price increase. Future share issuances could lead to dilution.
• Employees: The company maintains a 401(k) plan, though no employer match was made in 2025. Executive compensation is designed to incentivize performance and retention.
• Creditors/Lenders: Maintaining Nasdaq listing is crucial for access to capital markets and potentially favorable borrowing terms. Delisting could negatively impact financing capabilities.

Next Steps

• Stockholders to vote on the proposed resolutions at the 2026 Annual Meeting of Stockholders.
• The Board of Directors will decide whether to implement the reverse stock split based on stockholder approval and other factors.
• If approved, the reverse stock split will be effected at a time and ratio determined by the Board, between 1-for-3 and 1-for-8.

Key Dates

Recommendation

The company is facing a critical Nasdaq listing requirement, necessitating a reverse stock split. While the board and governance are strong, the need for such a measure indicates underlying stock performance issues. The outcome of the reverse stock split and its impact on future capital raising and business development remain uncertain. Therefore, a 'hold' recommendation is prudent, pending further clarity on the effectiveness of the reverse split and the company's path to sustainable growth.

Keywords

Aprea Therapeutics, Annual Meeting, Proxy Statement, Reverse Stock Split, Nasdaq Listing, Director Election, Executive Compensation, Independent Auditor, Corporate Governance